{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:29:55Z","timestamp":1782570595433,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"phrci grand ouest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Aquagenic pruritus (AP), an intense sensation of scratching induced after water contact, is the most troublesome aspect of BCR-ABL1-negative myeloproliferative neoplasms (MPNs). Mostly described in polycythemia vera (PV, ~\u200940%), it is also present in essential thrombocythemia (ET) and primary myelofibrosis (PMF) (10%). Even if this symptom can decrease or disappear under cytoreductive treatments, 30% of treated MPN patients still persist with a real impact on the quality of life (QoL). Because its pathophysiology is poorly understood, efficient symptomatic treatments of AP are missing. The neuropeptide substance P (SP) plays a crucial role in the induction of pruritus. Several studies showed the efficacy of aprepitant, an antagonist of SP receptor (NK-1R), in the treatment of chronic pruritus but never evaluated in AP. The objectives of APHYPAP are twofold: a clinical aim with the evaluation of the efficacy of two drugs in the treatment of a persistent AP for MPN patients and a biological aim to find clues to elucidate AP pathophysiology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods\/design<\/jats:title><jats:p>A multicentric, double-blind, double-placebo, randomized study will include 80 patients with MPN (PV or ET or PMF) treated since at least 6\u2009months for their hemopathy but suffering from a persistent AP (VAS intensity \u22656\/10). Patients will be randomized between aprepitant (80\u2009mg daily) + placebo to match to hydroxyzine OR hydroxyzine (25\u2009mg daily) + placebo to match to aprepitant for 14\u2009days. At D0, baseline information will be collected and drugs dispense. Outcome measures will be assessed at D15, D30, D45, and D60. The primary study endpoint will be the reduction of pruritus intensity below (or equal) at 3\/10 on VAS at D15. Secondary outcome measures will include the number of patients with a reduction or cessation of AP at D15 or D60; evaluation of QoL and AP characteristics at D0, D15, D30, D45, and D60 with MPN-SAF and AP questionnaires, respectively; modification of plasmatic concentrations of cytokines and neuropeptides at D0, D15, D30, and D60; and modification of epidermal innervation density and pruriceptor expression at D0 and D15.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The APHYPAP trial will examine the efficacy of aprepitant vs hydroxyzine (reference treatment for AP) to treat persistent AP in MPN patients. The primary objective is to demonstrate the superiority of aprepitant vs hydroxyzine to treat persistent AP of MPN patients. The treatment received will be considered efficient if the AP intensity will be reduced at 3\/10 or below on VAS after 14\u2009days of treatment. The results of this study may provide a new treatment option for this troublesome symptom and also give us more insights in the pathophysiology understanding of AP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>APHYPAP.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03808805?term=APHYPAP&amp;recrs=ab&amp;cntry=FR&amp;city=Brest&amp;draw=2&amp;rank=1\">NCT03808805<\/jats:ext-link>, first posted: January 18, 2019; last update posted: June 10, 2021. EudraCT 2018-090426-66<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-021-05864-8","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T15:02:35Z","timestamp":1639926155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP"],"prefix":"10.1186","volume":"22","author":[{"given":"C.","family":"Le Gall-Ianotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Verdet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Carlhant-Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marcorelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Misery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"issue":"2","key":"5864_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.","journal-title":"Blood Cancer J"},{"issue":"1","key":"5864_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bjd.14809","volume":"176","author":"C Le Gall-Ianotto","year":"2017","unstructured":"Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, et al. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol. 2017;176(1):255\u20138.","journal-title":"Br J Dermatol"},{"issue":"11","key":"5864_CR3","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/jth.14588","volume":"17","author":"C Le Gall-Ianotto","year":"2019","unstructured":"Le Gall-Ianotto C, Le Calloch R, Couturier MA, Chauveau A, Lippert E, Carr\u00e9 JL, et al. Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis. J Thromb Haemost. 2019;17(11):1950\u20135.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"5864_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617\u2009V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840\u20136.","journal-title":"Blood."},{"issue":"5","key":"5864_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2340\/00015555-2906","volume":"98","author":"E Lelonek","year":"2018","unstructured":"Lelonek E, Matusiak \u0141, Wr\u00f3bel T, Szepietowski JC. Aquagenic pruritus in polycythemia vera: clinical characteristics. Acta Derm Venereol. 2018;98(5):496\u2013500.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"5864_CR6","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030\u20136.","journal-title":"Blood."},{"issue":"24","key":"5864_CR7","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803\u201310.","journal-title":"Blood."},{"issue":"14","key":"5864_CR8","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","volume":"123","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157\u201360.","journal-title":"Blood."},{"issue":"23","key":"5864_CR9","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1182\/blood-2014-04-569137","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F. PDGFRB disease: right diagnosis to prolong survival. Blood. 2014;123(23):3526\u20138.","journal-title":"Blood."},{"issue":"5","key":"5864_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"9","key":"5864_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1365-2362.2010.02334.x","volume":"40","author":"KS Saini","year":"2010","unstructured":"Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828\u201334.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"5864_CR12","first-page":"356","volume":"13","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S. New therapies for polycythemia vera. Clin Adv Hematol Oncol. 2015;13(6):356\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"5864_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2340\/00015555-1400","volume":"92","author":"E Weisshaar","year":"2012","unstructured":"Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563\u201381.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"5864_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1600-0625.2011.01421.x","volume":"21","author":"N Lebonvallet","year":"2012","unstructured":"Lebonvallet N, Boulais N, Le Gall C, Pereira U, Gauch\u00e9 D, Gobin E, et al. Effects of the re-innervation of organotypic skin explants on the epidermis. Exp Dermatol. 2012;21(2):156\u20138.","journal-title":"Exp Dermatol"},{"issue":"6","key":"5864_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ana.25912","volume":"88","author":"M Talagas","year":"2020","unstructured":"Talagas M, Lebonvallet N, Leschiera R, Sinquin G, Elies P, Haftek M, et al. Keratinocytes communicate with sensory neurons via synaptic-like contacts. Ann Neurol. 2020;88(6):1205\u201319.","journal-title":"Ann Neurol"},{"issue":"3","key":"5864_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2340\/00015555-2235","volume":"96","author":"V Buh\u00e9","year":"2016","unstructured":"Buh\u00e9 V, Vi\u00e9 K, Gu\u00e9r\u00e9 C, Natalizio A, Lh\u00e9ritier C, Le Gall-Ianotto C, et al. Pathophysiological study of sensitive skin. Acta Derm Venereol. 2016;96(3):314\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"5864_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/bjd.17082","volume":"179","author":"F Huet","year":"2018","unstructured":"Huet F, Dion A, Batardi\u00e8re A, Nedelec AS, Le Ca\u00ebr F, Bourgeois P, et al. Sensitive skin can be small fibre neuropathy: results from a case-control quantitative sensory testing study. Br J Dermatol. 2018;179(5):1157\u201362.","journal-title":"Br J Dermatol"},{"issue":"12","key":"5864_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/exd.13991","volume":"28","author":"F Huet","year":"2019","unstructured":"Huet F, Misery L. Sensitive skin is a neuropathic disorder. Exp Dermatol. 2019;28(12):1470\u20133.","journal-title":"Exp Dermatol"},{"issue":"3","key":"5864_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s10517-015-2951-4","volume":"159","author":"AA Kubanov","year":"2015","unstructured":"Kubanov AA, Katunina OR, Chikin VV. Expression of neuropeptides, neurotrophins, and neurotransmitters in the skin of patients with atopic dermatitis and psoriasis. Bull Exp Biol Med. 2015;159(3):318\u201322.","journal-title":"Bull Exp Biol Med"},{"issue":"5","key":"5864_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1365-2230.1995.tb01354.x","volume":"20","author":"MS Al'Abadie","year":"1995","unstructured":"Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study. Clin Exp Dermatol. 1995;20(5):384\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"5864_CR21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2340\/0001555576282286","volume":"76","author":"V Staniek","year":"1996","unstructured":"Staniek V, Misery L, Peguet-Navarro J, Sabido O, Cuber JC, Dezutter-Dambuyant C, et al. Expression of gastrin-releasing peptide receptor in human skin. Acta Derm Venereol. 1996;76(4):282\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"2 Pt 1","key":"5864_CR22","first-page":"195","volume":"130","author":"L Misery","year":"2003","unstructured":"Misery L, Meyronet D, Pichon M, Brutin JL, Pestre P, Cambazard F. Aquadynia: a role for VIP? Ann Dermatol Venereol. 2003;130(2 Pt 1):195\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"5864_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0022-510X(95)00097-L","volume":"130","author":"O Johansson","year":"1995","unstructured":"Johansson O. The innervation of the human epidermis. J Neurol Sci. 1995;130(2):228.","journal-title":"J Neurol Sci"},{"issue":"5","key":"5864_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1365-2133.2011.10241.x","volume":"164","author":"B Amatya","year":"2011","unstructured":"Amatya B, El-Nour H, Holst M, Theodorsson E, Nordlind K. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol. 2011;164(5):1023\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"5864_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1365-2133.1994.tb08612.x","volume":"131","author":"G Hautmann","year":"1994","unstructured":"Hautmann G, Teofoli P, Lotti T. Aquagenic pruritus, PUVA and capsaicin treatments. Br J Dermatol. 1994;131(6):920\u20131.","journal-title":"Br J Dermatol"},{"issue":"2","key":"5864_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s002770050207","volume":"73","author":"M Jeanmougin","year":"1996","unstructured":"Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol. 1996;73(2):91\u20133.","journal-title":"Ann Hematol"},{"issue":"2 Pt 1","key":"5864_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0190-9622(94)70022-2","volume":"30","author":"T Lotti","year":"1994","unstructured":"Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. J Am Acad Dermatol. 1994;30(2 Pt 1):232\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5864_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2133.1993.tb03520.x","volume":"129","author":"HD Menag\u00e9","year":"1993","unstructured":"Menag\u00e9 HD, Norris PG, Hawk JL, Graves MW. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol. 1993;129(2):163\u20135.","journal-title":"Br J Dermatol"},{"issue":"5","key":"5864_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1046\/j.1365-2133.2002.04983.x","volume":"147","author":"A Baldo","year":"2002","unstructured":"Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol. 2002;147(5):979\u201381.","journal-title":"Br J Dermatol"},{"issue":"12","key":"5864_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/j.1600-0560.2007.00927.x","volume":"34","author":"MB Abdel-Naser","year":"2007","unstructured":"Abdel-Naser MB, Zaki MS, Mousa MH, Hamed H, Rizk MS, Mohamed HE, et al. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J Cutan Pathol. 2007;34(12):924\u20139.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"5864_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","volume":"40","author":"MDC Cacemiro","year":"2018","unstructured":"Cacemiro MDC, Cominal JG, Tognon R, Nunes NS, Sim\u00f5es BP, Figueiredo-Pontes LL, et al. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. Hematol Transfus Cell Ther. 2018;40(2):120\u201331.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"11","key":"5864_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003\u20135.","journal-title":"Am J Hematol"},{"issue":"10","key":"5864_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.leukres.2006.12.024","volume":"31","author":"CL Ho","year":"2007","unstructured":"Ho CL, Lasho TL, Butterfield JH, Tefferi A. Global cytokine analysis in myeloproliferative disorders. Leuk Res. 2007;31(10):1389\u201392.","journal-title":"Leuk Res"},{"key":"5864_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/964613","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Hasselbalch HC, \u010coki\u0107 V. Mediators of inflammation in myeloproliferative neoplasms: state of the art. Mediators Inflamm. 2015;2015:964613.","journal-title":"Mediators Inflamm"},{"key":"5864_CR35","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476.36.","journal-title":"Mediators Inflamm"},{"issue":"10","key":"5864_CR36","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356\u201363.","journal-title":"J Clin Oncol"},{"issue":"89","key":"5864_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102565","volume":"27","author":"A Jain","year":"2021","unstructured":"Jain A, Deo P, Sachdeva MUS, Bose P, Pad P, Prakash G, et al. Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. Blood Cells Mol Dis. 2021;27(89):102565.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"5864_CR38","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1038\/s41598-020-63680-7","volume":"10","author":"MDC Cacemiro","year":"2020","unstructured":"Cacemiro MDC, Cominal JG, Berzoti-Coelho MG, Tognon R, Nunes NS, Sim\u00f5es B, et al. Differential cytokine network profile in polycythemia vera and secondary polycythemia. Sci Rep. 2020;10(1):7032.","journal-title":"Sci Rep"},{"issue":"23","key":"5864_CR39","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1182\/blood-2008-09-179416","volume":"113","author":"T Ishii","year":"2009","unstructured":"Ishii T, Wang J, Zhang W, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113(23):5942\u201350. 40.","journal-title":"Blood."},{"issue":"7","key":"5864_CR40","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","volume":"5","author":"SR Dillon","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752\u201360.","journal-title":"Nat Immunol"},{"issue":"4","key":"5864_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","volume":"67","author":"K Ahern","year":"2012","unstructured":"Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760\u20138.42.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5864_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","volume":"138","author":"M Feld","year":"2016","unstructured":"Feld M, Garcia R, Buddenkotte J, Katayama S, Lewis K, Muirhead G, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500\u2013508.e24.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5864_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","volume":"73","author":"M Furue","year":"2018","unstructured":"Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29\u201336.","journal-title":"Allergy."},{"key":"5864_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-030-55617-4_8","volume":"1290","author":"AH Rook","year":"2021","unstructured":"Rook AH, Rook KA, Lewis DJ. Interleukin-31, a potent pruritus-inducing cytokine and its role in inflammatory disease and in the tumor microenvironment. Adv Exp Med Biol. 2021;1290:111\u201327.","journal-title":"Adv Exp Med Biol"},{"issue":"1-2","key":"5864_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellimm.2012.07.003","volume":"278","author":"S Gangemi","year":"2012","unstructured":"Gangemi S, Allegra A, Pace E, Alonci A, Ferraro M, Petrungaro A, et al. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol. 2012;278(1-2):91\u20134.","journal-title":"Cell Immunol"},{"issue":"3","key":"5864_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1046\/j.1365-2141.2001.03161.x","volume":"115","author":"F Diehn","year":"2001","unstructured":"Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol. 2001;115(3):619\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"5864_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/120347541201600304","volume":"16","author":"SM Herman-Kideckel","year":"2012","unstructured":"Herman-Kideckel SM, Binkley K. Successful treatment of aquagenic pruritus with montelukast. J Cutan Med Surg. 2012;16(3):151\u20132.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"5864_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1540-9740.2007.05880.x","volume":"6","author":"M Shohrati","year":"2007","unstructured":"Shohrati M, Tajik A, Harandi AA, Davoodi SM, Akmasi M. Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard. Skinmed. 2007;6(2):70\u20132.","journal-title":"Skinmed."},{"issue":"12","key":"5864_CR49","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1111\/jdv.15905","volume":"33","author":"K Agelopoulos","year":"2019","unstructured":"Agelopoulos K, R\u00fclander F, Dangelmaier J, Lotts T, Osada N, Metze D, et al. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1\/2 activation. J Eur Acad Dermatol Venereol. 2019;33(12):2371\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"5864_CR50","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/1752-1947-8-300","volume":"8","author":"JJA Villafranca","year":"2014","unstructured":"Villafranca JJA, Siles MG, Casanova M, Goitia BT, Dom\u00ednguez AR. Paraneoplastic pruritus presenting with Hodgkin\u2019s lymphoma: a case report. J Med Case Reports. 2014;8(8):300.","journal-title":"J Med Case Reports"},{"issue":"7","key":"5864_CR51","first-page":"557","volume":"12","author":"T Lotts","year":"2014","unstructured":"Lotts T, St\u00e4nder S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges. 2014;12(7):557\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"5864_CR52","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ad.2013.07.007","volume":"105","author":"HA Borja-Consigliere","year":"2014","unstructured":"Borja-Consigliere HA, L\u00f3pez-Pesta\u00f1a A, Vidal-Mance\u00f1ido MJ, Tuneu-Valls A. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. Actas Dermosifiliogr. 2014;105(7):716\u20138.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"5864_CR53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12885-017-3194-8","volume":"17","author":"JS Song","year":"2017","unstructured":"Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC Cancer. 2017;17(1):200.","journal-title":"BMC Cancer"},{"issue":"5","key":"5864_CR54","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/bjd.16374","volume":"178","author":"L Maro\u00f1as-Jim\u00e9nez","year":"2018","unstructured":"Maro\u00f1as-Jim\u00e9nez L, Ortiz-Romero PL. Aprepitant did not modify global disease activity in cutaneous T-cell lymphomas. Br J Dermatol. 2018;178(5):1222\u20133.","journal-title":"Br J Dermatol"},{"issue":"8","key":"5864_CR55","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1111\/jdv.16370","volume":"34","author":"A Pulido-Perez","year":"2020","unstructured":"Pulido-Perez A, Carretero-Lopez F, Bergon-Sendin M, Nieto-Benito LM, Romero-Jimenez R, Dorado-Herrero N, et al. Aprepitant in refractory pruritus of systemic lymphoproliferative disorders. Eur Acad Dermatol Venereol. 2020;34(8):e422\u20134.","journal-title":"Eur Acad Dermatol Venereol"},{"issue":"33","key":"5864_CR56","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"key":"5864_CR57","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1468-1331.2005.01260.x","volume":"12","author":"G Lauria","year":"2005","unstructured":"Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI, Nolano M, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol. 2005;12:747\u201358.","journal-title":"Eur J Neurol"},{"issue":"6","key":"5864_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ajh.21156","volume":"83","author":"N Gangat","year":"2008","unstructured":"Gangat N, Strand JJ, Lasho TL, et al. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol. 2008;83(6):451\u20133.","journal-title":"Am J Hematol"},{"key":"5864_CR59","unstructured":"Ritchie MK, Kohli A Aprepitant. 2020 In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan\u2013."},{"issue":"1","key":"5864_CR60","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.jaad.2011.01.016","volume":"66","author":"T Torres","year":"2012","unstructured":"Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5864_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010968","volume":"5","author":"S St\u00e4nder","year":"2010","unstructured":"St\u00e4nder S, Siepmann D, Herrgott I, Sunderk\u00f6tter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.","journal-title":"PLoS One"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05864-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:26:58Z","timestamp":1699968418000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05864-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,19]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["5864"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05864-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,19]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol as well as information and informed consent form has been approved by the ethical committee of Ile-De-France 8 in July 2018. ANSM has also approved the study. Signed and written informed consent will be obtained for all patients included in this study. Participants have the right to withdraw from the study at any time and for any reason.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"There is no need to obtain consent for publication since no identifying images or personal details of patients are presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"LM declares having interest with Novartis and UCB. JCI declares having interests with Novartis. The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"938"}}